BioSpace News Archive

Avacta Group plc, a clinical stage biopharmaceutical company developing innovative cancer therapies and powerful diagnostics based on its proprietary Affimer® and pre|CISION™ platforms, is pleased to announce that the first patient has been dosed in its Phase I multicentre trial evaluating AVA6000, a novel pro-drug of Doxorubicin.

Reneo Pharmaceuticals, Inc., a clinical stage pharmaceutical company focused on the development and commercialization of therapies for patients with rare genetic, mitochondrial diseases, reported financial results for the quarter ended June 30, 2021 and provided an update on its clinical programs.

Berkeley Lights, Inc. a leader in the functional characterization of live biology, announced a multi-year agreement with Bayer to develop and perform high-throughput functional screening workflows aimed at accelerating and expanding the discovery of novel traits.

Inozyme Pharma, Inc., a rare disease biopharmaceutical company developing novel therapeutics for the treatment of abnormal mineralization, reported financial results for the second quarter ended June 30, 2021, and provided recent business highlights.

BD, a leading global medical technology company, announced that Christopher DelOrefice has been named executive vice president and chief financial officer, effective Sept. 6, 2021.

Researchers at Ben-Gurion University of the Negev are developing a novel therapeutic strategy for treating Inflammatory Bowel Diseases by sequestering inflammation-inducing molecules secreted by gut bacteria.

Bio-Thera Solutions, Ltd. announced the discovery of a broad-spectrum SARS-CoV-2 neutralizing antibody with the potential to treat COVID-19.

Berkeley Lights, Inc., a leader in Digital Cell Biology, reported financial results for the quarter ended June 30, 2021.

Haemonetics Corporation announced that financial results for its first quarter fiscal 2022, which ended July 3, 2021, are available on its Investor Relations website.

GentiBio, Inc., a biotherapeutics company developing engineered regulatory T cells therapies for immunology, announced it has closed on a Series A financing generating immediate proceeds of $157 million, led by Matrix Capital Management with participation by Avidity Partners, JDRF T1D Fund, seed investors OrbiMed, RA Capital Management, and Novartis Venture Fund, and Seattle Children’s Research Institute.